Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for GLASDEGIB
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
- CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
- Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML
- Glasdegib for Chronic Graft-Versus-Host Disease
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
- Molecular Profiling of Advanced Soft-tissue Sarcomas
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
- Glasdegib Renal Impairment Study
- Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Glasdegib Absolute Bioavailability Study
- Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia
- A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects
- A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation
- Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Clinical trials list
click for details